4//SEC Filing
Jones Adrian M 4
Accession 0000899243-21-031361
CIK 0001492674other
Filed
Aug 2, 8:00 PM ET
Accepted
Aug 3, 6:39 PM ET
Size
190.8 KB
Accession
0000899243-21-031361
Insider Transaction Report
Form 4
Jones Adrian M
Director
Transactions
- Purchase
Common Stock
2020-05-19$0.83/sh+10,328$8,602→ 4,199,287 total(indirect: See Footnotes) - Sale
Common Stock
2020-05-19$0.83/sh−800$668→ 4,198,487 total(indirect: See Footnotes) - Sale
Common Stock
2020-05-06$0.57/sh−2,000$1,140→ 4,197,456 total(indirect: See Footnotes) - Purchase
Common Stock
2020-05-20$0.80/sh+5,126$4,116→ 4,201,582 total(indirect: See Footnotes) - Purchase
Common Stock
2020-04-09$0.49/sh+1,000$490→ 4,197,456 total(indirect: See Footnotes) - Purchase
Common Stock
2020-05-06$0.55/sh+26,200$14,455→ 4,209,556 total(indirect: See Footnotes) - Sale
Common Stock
2020-05-19$0.83/sh−3,235$2,691→ 4,193,021 total(indirect: See Footnotes) - Purchase
Common Stock
2020-03-24$0.38/sh+500$189→ 4,196,956 total(indirect: See Footnotes) - Sale
Common Stock
2020-03-24$0.38/sh−500$189→ 4,196,456 total(indirect: See Footnotes) - Sale
Common Stock
2020-03-25$0.93/sh−600$557→ 4,196,456 total(indirect: See Footnotes) - Sale
Common Stock
2020-05-06$0.52/sh−2,655$1,381→ 4,193,801 total(indirect: See Footnotes) - Sale
Common Stock
2020-05-06$0.53/sh−50$27→ 4,191,251 total(indirect: See Footnotes) - Sale
Common Stock
2020-05-06$0.55/sh−100$55→ 4,184,295 total(indirect: See Footnotes) - Sale
Common Stock
2020-05-19$0.83/sh−2,031$1,691→ 4,188,959 total(indirect: See Footnotes) - Sale
Common Stock
2020-05-06$0.53/sh−500$266→ 4,190,751 total(indirect: See Footnotes) - Sale
Common Stock
2020-05-06$0.57/sh−10,100$5,757→ 4,199,456 total(indirect: See Footnotes) - Sale
Common Stock
2020-05-12$0.55/sh−2,500$1,365→ 4,196,456 total(indirect: See Footnotes) - Purchase
Common Stock
2020-03-25$0.93/sh+600$557→ 4,197,056 total(indirect: See Footnotes) - Sale
Common Stock
2020-05-06$0.52/sh−1,000$521→ 4,192,801 total(indirect: See Footnotes) - Sale
Common Stock
2020-05-06$0.53/sh−1,000$526→ 4,191,801 total(indirect: See Footnotes) - Sale
Common Stock
2020-05-06$0.53/sh−500$264→ 4,191,301 total(indirect: See Footnotes) - Sale
Common Stock
2020-05-06$0.54/sh−6,256$3,378→ 4,184,395 total(indirect: See Footnotes) - Sale
Common Stock
2020-05-06$0.55/sh−939$517→ 4,183,356 total(indirect: See Footnotes) - Sale
Common Stock
2020-05-06$0.57/sh−1,000$570→ 4,196,456 total(indirect: See Footnotes) - Sale
Common Stock
2020-05-19$0.83/sh−200$166→ 4,196,256 total(indirect: See Footnotes) - Sale
Common Stock
2020-05-19$0.83/sh−2,031$1,691→ 4,190,990 total(indirect: See Footnotes) - Sale
Common Stock
2020-05-19$0.83/sh−2,031$1,695→ 4,196,456 total(indirect: See Footnotes) - Sale
Common Stock
2020-04-09$0.49/sh−1,000$490→ 4,196,456 total(indirect: See Footnotes) - Sale
Common Stock
2020-05-06$0.53/sh−100$53→ 4,190,651 total(indirect: See Footnotes) - Purchase
Common Stock
2020-05-12$0.55/sh+2,500$1,365→ 4,198,956 total(indirect: See Footnotes)
Footnotes (5)
- [F1]These transactions in the common stock (the "Common Stock") of T2 Biosystems, Inc. (the "Issuer") have not previously been reported on Form 4 and were effected by Goldman Sachs & Co. LLC ("Goldman Sachs") acting as agent on behalf of certain international affiliates that had entered into riskless principal trades in connection with client trade facilitation in the ordinary course of their business.
- [F2]Without conceding riskless principal trades in connection with client trade facilitation in the ordinary course of business can result in liability under Section 16(b) of the Securities Exchange Act of 1934 (the "Exchange Act"), the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer.
- [F3]The Reporting Person is a managing director of Goldman Sachs. Goldman Sachs is a subsidiary of The Goldman Sachs Group, Inc. ("GS Group").
- [F4]GS Group and Goldman Sachs may be deemed to beneficially own indirectly, in the aggregate, 4,157,240 shares of Common Stock of the Issuer by reason of the direct beneficial ownership of Common Stock by certain investment entities (the "GS Funds") because GS Group, or affiliates of GS Group and Goldman Sachs, are the general partner, managing general partner, managing partner, managing member or member of each of the GS Funds. Goldman Sachs beneficially owns directly and GS Group may be deemed to beneficially own indirectly 29,216 shares of common stock.
- [F5]The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Issuer
T2 Biosystems, Inc.
CIK 0001492674
Entity typeother
Related Parties
1- filerCIK 0001359316
Filing Metadata
- Form type
- 4
- Filed
- Aug 2, 8:00 PM ET
- Accepted
- Aug 3, 6:39 PM ET
- Size
- 190.8 KB